Vijaya Ramesh
YOU?
Author Swipe
View article: Asymptomatic Metastatic Renal Cell Carcinoma Presenting as Acute Intracerebral Hemorrhage in a Geriatric Patient
Asymptomatic Metastatic Renal Cell Carcinoma Presenting as Acute Intracerebral Hemorrhage in a Geriatric Patient Open
The complex association between acute neurological events and underlying malignancies presents significant challenges for clinicians, especially in elderly patients where manifestations can be atypical. Intracerebral hemorrhages (ICHs), co…
View article: <i>TSC2</i>loss in neural progenitor cells suppresses translation of ASD/NDD-associated transcripts in an mTORC1- and MNK1/2-reversible fashion
<i>TSC2</i>loss in neural progenitor cells suppresses translation of ASD/NDD-associated transcripts in an mTORC1- and MNK1/2-reversible fashion Open
SUMMARY Tuberous sclerosis complex (TSC) is an inherited neurodevelopmental disorder (NDD) with frequent manifestations of epilepsy and autism spectrum disorder (ASD). TSC is caused by inactivating mutations in TSC1 or TSC2 tumor suppresso…
View article: Evolving concepts in meningioma management in the era of genomics
Evolving concepts in meningioma management in the era of genomics Open
Meningioma is the most common type of primary brain tumor. Surgical resection followed by surveillance is the first‐line treatment for the majority of symptomatic meningiomas; however, recent advances in molecular sequencing, DNA methylati…
View article: Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2 Open
View article: Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in <i>NF2</i>-deficient models
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in <i>NF2</i>-deficient models Open
Background NF2-associated meningiomas are progressive, highly morbid, and nonresponsive to chemotherapies, highlighting the need for improved treatments. We have established aberrant activation of the mechanistic target of rapamycin (mTOR)…
View article: Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations Open
Background Tuberous sclerosis complex (TSC) is an inherited neurocutaneous disorder caused by mutations in the TSC1 or TSC2 genes, with patients often exhibiting neurodevelopmental (ND) manifestations termed TSC-associated neuropsychiatric…
View article: Data from Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2–Deficient Target Cell Types
Data from Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2–Deficient Target Cell Types Open
Inactivating mutations in the neurofibromatosis 2 (NF2) tumor suppressor gene results in the development of schwannomas and meningiomas. Using NF2-deficient meningioma cells and tumors, together with the normal cellular counterparts…
View article: Data from Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2–Deficient Target Cell Types
Data from Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2–Deficient Target Cell Types Open
Inactivating mutations in the neurofibromatosis 2 (NF2) tumor suppressor gene results in the development of schwannomas and meningiomas. Using NF2-deficient meningioma cells and tumors, together with the normal cellular counterparts…
View article: Supplementary Figure 1 from Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2–Deficient Target Cell Types
Supplementary Figure 1 from Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2–Deficient Target Cell Types Open
PDF file - 105K, Receptor phosphorylation in merlin-deficient Schwann cells in response to serum deprivation, IGF-1 and PDGF stimulation
View article: Supplementary Figure 1 from Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2–Deficient Target Cell Types
Supplementary Figure 1 from Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2–Deficient Target Cell Types Open
PDF file - 105K, Receptor phosphorylation in merlin-deficient Schwann cells in response to serum deprivation, IGF-1 and PDGF stimulation
View article: Translatome analysis of Tuberous Sclerosis Complex-1 patient-derived neural progenitor cells reveal rapamycin-dependent and independent alterations
Translatome analysis of Tuberous Sclerosis Complex-1 patient-derived neural progenitor cells reveal rapamycin-dependent and independent alterations Open
View article: Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma
Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma Open
Background Neurofibromatosis 2 (NF2) is an inherited disorder caused by bi-allelic inactivation of the NF2 tumor suppressor gene. NF2-associated tumors, including schwannoma and meningioma, are resistant to chemotherapy, often recurring de…
View article: Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2 Open
Background Meningiomas occur in 80% of persons with neurofibromatosis 2 (NF2) and cause significant mortality and morbidity, yet there are no effective medical treatments. NF2-deficient tumors have constitutive activation of mammalian/mech…
View article: Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2 Open
Loss of function of the neurofibromatosis type 2 (NF2) tumor suppressor gene leads to the formation of schwannomas, meningiomas, and ependymomas, comprising ∼50% of all sporadic cases of primary nervous system tumors. NF2 syndrome is an au…
View article: SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma
SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma Open
View article: CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION
CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION Open
Grade II/III meningiomas have increased rates of recurrence with no approved medical therapies. The historical progression-free survival at 6 months (PFS-6) is 25% with rates >35% declared of interest for drug development. NF2 gene inac…
View article: High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy
High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy Open
View article: Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK Open
Neurofibromatosis Type 2 (NF2) is an autosomal dominant genetic syndrome caused by mutations in the NF2 tumor suppressor gene resulting in multiple schwannomas and meningiomas. There are no FDA approved therapies for these tumors and their…
View article: Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin
Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin Open
Gene therapy for tuberous sclerosis type 2 proved beneficial in a mouse model of the disease, extending life span.
View article: mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition
mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition Open
Meningiomas (MNs), arising from the arachnoid/meningeal layer, are nonresponsive to chemotherapies, with ∼50% showing loss of the Neurofibromatosis 2 (NF2) tumor suppressor gene. Previously, we established NF2 loss activates mechanistic ta…
View article: Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma
Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma Open
Neurofibromatosis type 2 (NF2) is an inherited disorder characterized by bilateral vestibular schwannomas (VS) that arise from neoplastic Schwann cells (SCs). NF2-associated VSs are often accompanied by meningioma (MN), and the majority of…
View article: TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling
TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling Open
Background Tuberous sclerosis complex (TSC) is a neurodevelopmental disorder with frequent occurrence of epilepsy, autism spectrum disorder (ASD), intellectual disability (ID), and tumors in multiple organs. The aberrant activation of mTOR…
View article: First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics
First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics Open
The neurofibromatoses, which include neurofibromatosis type I (NF1), neurofibromatosis type II (NF2), and schwannomatosis, are a group of syndromes characterized by tumor growth in the nervous system. The RASopathies are a group of syndrom…
View article: ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS
ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS Open
Meningiomas are the second most common tumor in NF2 patients, with a cumulative prevalence of 80% by age 70 and a high prevalence of multiple meningiomas. Surgery remains standard of care for these tumors, yet outcomes remain suboptimal fo…
View article: CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA
CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA Open
Meningiomas (MN), the most common adult primary intracranial tumor, arise from the arachnoid/meninges and are non-responsive to chemotherapies with a high recurrence rate despite surgery, necessitating effective non-invasive therapies. Our…
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2 Open
View article: EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma Open
Co-targeting mTORC1/2 and EPH RTK/SFK pathways could be a novel effective treatment strategy for NF2-deficient meningiomas.
View article: Pain correlates with germline mutation in schwannomatosis
Pain correlates with germline mutation in schwannomatosis Open
Schwannomatosis has been linked to germline mutations in the SMARCB1 and LZTR1 genes, and is frequently associated with pain.In a cohort study, we assessed the mutation status of 37 patients with clinically diagnosed schwannomatosis and co…
View article: A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus
A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus Open
We established a new patient-derived meningioma model that will enable the study of targeted therapeutic approaches for HGM. Based on these studies, it is reasonable to consider a clinical trial of G47Δ for HGM.
View article: <i>Agrobacterium</i> mediated transient transfer of <i>xopQ</i>, <i>xopX</i> and <i>xopZ</i> genes of <i>Xanthomonas</i><i>oryzae</i> pv. <i>oryzae</i> suppresses LipA induced callose deposition in rice leaves.
<i>Agrobacterium</i> mediated transient transfer of <i>xopQ</i>, <i>xopX</i> and <i>xopZ</i> genes of <i>Xanthomonas</i><i>oryzae</i> pv. <i>oryzae</i> suppresses LipA induced callose deposition in rice leaves. Open
Rice leaves were infiltrated with one of the following: buffer + Estradiol (Est; A); LipA + Est (B); EHA105/pMDC7-xopQ + LipA with Est (C) or without Est (D); EHA105/pMDC7-xopX + LipA with Est (…